DE2610504C2 - Eine von Pseudomonas aeruginosa stammende Komponente aus Zucker, Lipoid und Protein, mit Antitumor- und Interferon bildenden Eigenschaften - Google Patents

Eine von Pseudomonas aeruginosa stammende Komponente aus Zucker, Lipoid und Protein, mit Antitumor- und Interferon bildenden Eigenschaften

Info

Publication number
DE2610504C2
DE2610504C2 DE2610504A DE2610504A DE2610504C2 DE 2610504 C2 DE2610504 C2 DE 2610504C2 DE 2610504 A DE2610504 A DE 2610504A DE 2610504 A DE2610504 A DE 2610504A DE 2610504 C2 DE2610504 C2 DE 2610504C2
Authority
DE
Germany
Prior art keywords
oep
tumor
pseudomonas
interferon
protein component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2610504A
Other languages
German (de)
English (en)
Other versions
DE2610504A1 (de
Inventor
Chiyoji Prof. Yokohama Kanagawa Abe
Yuzuru Prof. Tokio/Tokyo Homma
Akio Prof. Tokio/Tokyo Hoshi
Kazuo Prof. Kuretani
Kenichi Prof. Tanamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tokyo NUC
Original Assignee
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tokyo NUC filed Critical University of Tokyo NUC
Publication of DE2610504A1 publication Critical patent/DE2610504A1/de
Application granted granted Critical
Publication of DE2610504C2 publication Critical patent/DE2610504C2/de
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/874—Pseudomonas
    • Y10S435/875—Pseudomonas aeruginosa

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Peptides Or Proteins (AREA)
DE2610504A 1975-05-14 1976-03-12 Eine von Pseudomonas aeruginosa stammende Komponente aus Zucker, Lipoid und Protein, mit Antitumor- und Interferon bildenden Eigenschaften Expired DE2610504C2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP50055979A JPS51133489A (en) 1975-05-14 1975-05-14 Process for producing microbial components of pseudomonas aeruginosa h aving antimicrobial and antitumor activities

Publications (2)

Publication Number Publication Date
DE2610504A1 DE2610504A1 (de) 1976-11-25
DE2610504C2 true DE2610504C2 (de) 1985-07-11

Family

ID=13014183

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2610504A Expired DE2610504C2 (de) 1975-05-14 1976-03-12 Eine von Pseudomonas aeruginosa stammende Komponente aus Zucker, Lipoid und Protein, mit Antitumor- und Interferon bildenden Eigenschaften

Country Status (7)

Country Link
US (1) US4079126A (OSRAM)
JP (1) JPS51133489A (OSRAM)
CA (1) CA1060797A (OSRAM)
DE (1) DE2610504C2 (OSRAM)
FR (1) FR2311093A1 (OSRAM)
GB (1) GB1537509A (OSRAM)
SE (1) SE434701B (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1085293A (en) * 1976-02-05 1980-09-09 Yuzuru Homma Toxoids derived from protease and elastase of pseudomonas aeruginosa and production thereof
JPS5296729A (en) * 1976-02-05 1977-08-13 Shionogi & Co Ltd Mixed vaccin for cyanomycosis
US4479935A (en) * 1980-04-22 1984-10-30 Institut Pasteur Fractions extracted from aerobic bacteria, endowed with antitumoral, antibacterial and interferon inducing properties, and process for their preparation
CA1256370A (en) * 1984-02-24 1989-06-27 Yuzuru Homma Toxoids of elastase of pseudomonas aeruginosa origin
AT384032B (de) * 1985-01-14 1987-09-25 Immuno Ag Verfahren zur herstellung von polydispersen nativen pseudomonas-flagella(h)-antigenen (fag)
US5179001A (en) * 1985-09-27 1993-01-12 The Regents Of The University Of California Detection and monitoring of chronic and gram-negative infection
US5237053A (en) * 1986-06-24 1993-08-17 Immuno Aktiengesellschaft Preparation active against Pseudomonas aeruginosa infections and methods of producing them
AT391080B (de) * 1986-06-24 1990-08-10 Immuno Ag Verfahren zur herstellung von gegen pseudomonas aeruginosa infektionen wirksamen praeparationen
FR2613380B1 (fr) * 1987-04-06 1989-11-17 Pasteur Institut Nouvelle substance adjuvante de certains antimitotiques chimiques, procede d'obtention de cette substance a partir de cultures de vibrio cholerae, agents therapeutiques contenant ladite substance
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
EP0497883B1 (en) * 1989-10-27 1998-07-15 Arch Development Corporation Compositions and their use for promoting immunopotentiation
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US20030108548A1 (en) * 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
SG177944A1 (en) * 2005-07-11 2012-02-28 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
AU2007260687B2 (en) * 2006-06-14 2013-12-12 Provention Bio, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
EP2094302A4 (en) * 2006-12-21 2010-12-08 Macrogenics Inc METHODS FOR THE TREATMENT OF LADA-LIKE DIABETES AND OTHER AUTOIMMUNE DIABETES OF THE ADULT USING IMMUNOSUPPRESSANT MONOCLONAL ANTIBODIES HAVING REDUCED TOXICITY
KR20140147657A (ko) * 2011-03-02 2014-12-30 제롬 쉔타그 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
CN109401992B (zh) * 2017-08-18 2021-07-23 黑龙江省科学院微生物研究所 一株高产内毒素蛋白的铜绿假单胞菌及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS496096B1 (OSRAM) * 1970-09-30 1974-02-12
FR2111719B1 (OSRAM) * 1970-10-20 1975-02-07 Yuzuru Homma
FR2184531B1 (OSRAM) * 1972-05-19 1975-10-17 Anvar

Also Published As

Publication number Publication date
SE434701B (sv) 1984-08-13
FR2311093B1 (OSRAM) 1979-06-29
JPS6123167B2 (OSRAM) 1986-06-04
SE7601841L (sv) 1976-11-15
US4079126A (en) 1978-03-14
CA1060797A (en) 1979-08-21
GB1537509A (en) 1978-12-29
FR2311093A1 (fr) 1976-12-10
DE2610504A1 (de) 1976-11-25
JPS51133489A (en) 1976-11-19

Similar Documents

Publication Publication Date Title
DE2610504C2 (de) Eine von Pseudomonas aeruginosa stammende Komponente aus Zucker, Lipoid und Protein, mit Antitumor- und Interferon bildenden Eigenschaften
DE68929208T2 (de) Anwendungen von Acemannan
DE60103066T2 (de) Chlorella zubereitungen mit immunmodulatorischen eigenschaften
DE2331144A1 (de) Wasserloesliche extrakte von mycobacterien
DE2751717A1 (de) Neue verbesserte gammaglobuline fuer intravenoese injektion und verfahren zu ihrer herstellung
DE2659808C3 (de) Proteingebundene Polysaccharide und deren Verwendung zur Bekämpfung von Tumoren
DE2610540A1 (de) Prophylaktisches mittel gegen die infektion von nerzen durch pseudomonas aeruginosa
DE3017372A1 (de) Physiologisch aktive polysaccharide, verfahren zu ihrer herstellung sowie ihre verwendung
DE69316026T2 (de) Als fischimpfstoff anwendbare attenuierte aeromonas salmonicida-stämme
CH641354A5 (de) Material mit antitumorwirkung und verfahren zu dessen herstellung.
DE2919132A1 (de) Substanz ks-2-b, verfahren zu deren herstellung und diese substanz enthaltende mittel
DE2024586A1 (de) Neue Verbindungen bakteriellen Ursprungs und Verfahren zu deren Herstellung
DE2704766C2 (OSRAM)
DE69220939T2 (de) Gegengift immunsera
DE69434424T2 (de) In vitro kulturprozess für verschiedene stadien von gewebeparasiten
GB2036751A (en) Interferon inducers methods for their preparation pharmaceutical compositions containing them and their use as medicaments
DE69112573T2 (de) Immunstimulierendes arzneimittel, das polare glycopeptidolipide von mycobakterium-chelonae enthält.
CH657989A5 (de) Biologisch aktive substanz, verfahren zur herstellung der substanz, sowie die substanz enthaltende, immunoaktive zusammensetzung.
DE3685700T2 (de) E87ag-antigen des pseudomonas aeruginosa, monoklonale antikoerper dagegen und hybridom.
DE2152112C3 (de) Impfstoff gegen Pseudomonas aeruginosa
US3987164A (en) Method for prevention of pseudomonas aeruginosa infections
DE2851629A1 (de) Biologisches peptolidpraeparat, verfahren zu seiner herstellung und dieses praeparat enthaltende arzneimittel
EP0320528B1 (de) Verwendung von Haemocyaninen und Arylphorinen zur Beeinflussung des Immmunsystems und Behandlung von Tumoren
DE2829975A1 (de) Antitumor wirksame substanz, deren herstellung und verwendung
DE2819035C2 (de) Antimikrobielle Substanz C-3603 und Verfahren zur Herstellung derselben

Legal Events

Date Code Title Description
8128 New person/name/address of the agent

Representative=s name: ZUMSTEIN SEN., F., DR. ASSMANN, E., DIPL.-CHEM. DR

D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee